| Title |
Efficacy of Anti-Interleukin-5 Therapy with Mepolizumab in Patients with Asthma: A Meta-Analysis of Randomized Placebo-Controlled Trials
|
|---|---|
| Published in |
PLOS ONE, March 2013
|
| DOI | 10.1371/journal.pone.0059872 |
| Pubmed ID | |
| Authors |
Yao Liu, Song Zhang, Dao-wei Li, Shu-juan Jiang |
| Abstract |
Interleukin (IL)-5 is believed to be a key cytokine in eosinophil inflammatory infiltration in asthma. Previous clinical trials have evaluated the efficacy and safety of mepolizumab, a monoclonal antibody against IL-5, in patients with asthma. However, most of these studies were small, the conclusions were inconsistent, and the precise effects are therefore debatable. |
X Demographics
The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 50% |
| Canada | 1 | 17% |
| Unknown | 2 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 50% |
| Scientists | 2 | 33% |
| Practitioners (doctors, other healthcare professionals) | 1 | 17% |
Mendeley readers
The data shown below were compiled from readership statistics for 116 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Korea, Republic of | 1 | <1% |
| United States | 1 | <1% |
| India | 1 | <1% |
| France | 1 | <1% |
| Unknown | 112 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 21 | 18% |
| Student > Ph. D. Student | 17 | 15% |
| Student > Master | 13 | 11% |
| Student > Bachelor | 13 | 11% |
| Student > Doctoral Student | 8 | 7% |
| Other | 25 | 22% |
| Unknown | 19 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 56 | 48% |
| Agricultural and Biological Sciences | 8 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 6% |
| Biochemistry, Genetics and Molecular Biology | 5 | 4% |
| Immunology and Microbiology | 5 | 4% |
| Other | 14 | 12% |
| Unknown | 21 | 18% |